BCL-2 as a therapeutic target in chronic lymphocytic leukemia.

Daniel, Catherine; Mato, Anthony R

Daniel, Catherine; Mato, Anthony R.

Affiliation

Daniel C; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
Mato AR; Center for Chronic Lymphocytic Leukemia, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.

Clin Adv Hematol Oncol ; 15(3): 210-218, 2017 Mar.

Article in En | MEDLINE | ID: mdl-28398276

Subject(s)

Antineoplastic Agents/therapeutic use; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell/metabolism; Molecular Targeted Therapy; Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors; Animals; Antineoplastic Agents/administration & dosage; Antineoplastic Agents/adverse effects; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Combined Modality Therapy; Disease Management; Humans; Leukemia, Lymphocytic, Chronic, B-Cell/mortality; Neutropenia/diagnosis; Neutropenia/drug therapy; Neutropenia/etiology; Proto-Oncogene Proteins c-bcl-2/metabolism; Receptors, Antigen, B-Cell/antagonists & inhibitors; Receptors, Antigen, B-Cell/metabolism; Signal Transduction/drug effects; Treatment Outcome; Tumor Lysis Syndrome/diagnosis; Tumor Lysis Syndrome/etiology; Tumor Lysis Syndrome/therapy

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / Proto-Oncogene Proteins c-bcl-2 / Molecular Targeted Therapy / Antineoplastic Agents Type of study: Diagnostic_studies / Etiology_studies Limits: Animals / Humans Language: En Year: 2017 Type: Article

Search on Google

XML

PubMed Links